Condition
Waldenstrom's Disease
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed2
Recruiting2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03952052Not ApplicableCompletedPrimary
Detection of Recurrent Mutations in Waldenström's Disease
NCT05911802RecruitingPrimary
Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease
NCT04893564Not ApplicableRecruitingPrimary
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
NCT03329950Phase 1Completed
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT03679624Phase 2Terminated
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Showing all 5 trials